Estimation of 8-iso-PGF2α as a marker of oxidative stress in T2DM patients with and without dyslipidemia
DOI:
https://doi.org/10.12923/cipms-2026-0001Keywords:
8-iso-prostaglandin-F2α, 8-iso-PGF2α, high sensitivity C-reactive protein, dyslipidemia, oxidative stress, type 2 diabetes mellitusAbstract
Oxidative stress resulting from excessive production of reactive oxygen species (ROS) plays a pivotal role in the development of chronic diseases, including type 2 diabetes mellitus (T2DM) and its related metabolic disturbances. This study aimed to assess the biomarker 8-iso-prostaglandin-F2α (8-iso-PGF2α) as an indicator of oxidative stress in T2DM patients and to investigate its association with dyslipidemia, with the objective of determining its potential value in predicting early diabetesrelated complications.
The study included 90 participants: 60 T2DM patients (30 with dyslipidemia and 30 without) and 30 age and sexmatched healthy controls. Fasting serum samples were analyzed for glucose and lipid profile using an autoanalyzer, while C-reactive protein (CRP) and 8-iso-PGF2α levels were measured using ELISA. Compared with healthy controls, patients with T2DM exhibited markedly elevated levels of oxidative stress and inflammatory markers, including significant increases in both 8-iso-PGF2α and CRP. Among individuals with T2DM, those with dyslipidemia showed substantially higher 8-iso-PGF2α concentrations and a slightly higher CRP levels compared with patients without dyslipidemia. Diagnostic assessment indicated that 8-iso-PGF2α showed moderate ability to distinguish T2DM patients with dyslipidemia from those without. These findings suggest that elevated 8-iso-PGF2α, particularly in dyslipidemic T2DM patients, may serve as a promising early marker for assessing the risk of T2DMassociated complications.
References
1. Mukhtar MH, ElEmshaty HM, Alamodi HS, Nasif WA. The activity of serum 8-iso-prostaglandin F2α as oxidative stress marker in patients with diabetes mellitus type 2 and associated dyslipidemic hyperglycemia. J Diabetes Mellitus. 2016;6(4):318. http://dx.doi.org/10.4236/jdm.2016.64033
2. Abed WG, AlShawk RS, Jassim KA. The role of insulin level on the biofilmforming capacity in diabetesrelated urinary tract infection. Mustansiriya Med J. 2021;20(2):66-70. http://dx.doi.org/10.4103/mj.mj_12_21
3. Dilworth L, Facey A, Omoruyi F. Diabetes mellitus and its metabolic complications: the role of adipose tissues. Int J Mol Sci. 2021;22(14):7644. https://doi.org/10.3390/ijms22147644
4. Jaid HK, Khaleel FM, Salman IN, Abd BA. Estimation of apelin levels in Iraqi patients with type II diabetic peripheral neuropathy. Baghdad Sci J. 2023;20(5):1684. https://dx.doi.org/10.21123/bsj.2023.ID
5. Abed BA, Farhan LO, Dawood AS. Relationship between serum nesfatin1, adiponectin, resistin concentration, and obesity with type 2 diabetes mellitus. Baghdad Sci J. 2024;21(1):117. https://doi.org/10.21123/bsj.2023.8119
6. Ali S, Rao NL, Amir S. Diabetic dyslipidemia: a screening tool for cardiovascular risk assessment. Biomed Res Ther. 2021;8(12):4775-81. https://doi.org/10.15419/bmrat.v8i12.713
7. Jasim AlTamimi MN, AlShawk RS, AlKarawi INS. The role of the proinflammatory cytokine interferongamma in type 2 diabetes and its correlation with atherosclerosis. Mustansiriya Med J. 2022;21(1):18-22. https://doi.org/10.4103/mj.mj_13_21
8. Kane JP, Pullinger CR, Goldfine ID, Malloy MJ. Dyslipidemia and diabetes mellitus: role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus. Curr Opin Pharmacol. 2021;61:21-7. https://doi.org/10.1016/j.coph.2021.08.013
9. Jomova K, Raptova R, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Arch Toxicol. 2023;97(10):2499-574. https://doi.org/10.1007/s00204023035629
10. Arif MA, Ahmeid MS, Allaw SA. Malondialdehyde level in the patients subjected to openheart surgery in association with lipid profile. Mustansiriya Med J. 2019;18(1):30-5. https://doi.org/10.4103/MJ.MJ_34_18
11. Vona R, Pallotta L, Cappelletti M, Severi C, Matarrese P. The impact of oxidative stress in human pathology: focus on gastrointestinal disorders. Antioxidants. 2021;10(2):201. https://doi.org/10.3390/antiox10020201
12. Azzi A. Oxidative stress: what is it? Can it be measured? Where is it located? Can it be good or bad? Can it be prevented? Can it be cured? Antioxidants. 2022;11(8):1431. https://doi.org/10.3390/antiox11081431
13. MasBargues C, Escriva C, Dromant M, Borras C, Vina J. Lipid peroxidation as measured by chromatographic determination of malondialdehyde: human plasma reference values in health and disease. Arch Biochem Biophys. 2021;709:108941. https://doi.org/10.1016/j.abb.2021.108941
14. Alharby H, Abdelati T, Rizk M, Youssef E, Moghazy K, Gaber N, et al. Association of lipid peroxidation and interleukin6 with carotid atherosclerosis in type 2 diabetes. Cardiovasc Endocrinol Metab. 2019;8(3):73-6. https://doi.org/10.1097/XCE.0000000000000175
15. Zheng L, Fei J, Feng CM, Xu Z, Fu L, Zhao H. Serum 8-iso-PGF2α predicts the severity and prognosis in patients with communityacquired pneumonia: a retrospective cohort study. Front Med. 2021;8:633442. https://doi.org/10.3389/fmed.2021.633442
16. Nono Nankam PA, Nguelefack TB, Goedecke JH, Blüher M. Contribution of adipose tissue oxidative stress to obesityassociated diabetes risk and ethnic differences: focus on women of African ancestry. Antioxidants. 2021;10(4):622. https://doi.org/10.3390/antiox10040622
17. Zhang Y, Du Y, He JF, Li KJ. 8-iso-prostaglandin F2α: a possible trigger or accelerator of diabetic retinopathy. Int J Ophthalmol. 2016;9(1):163. https://doi.org/10.18240/ijo.2016.01.27
18. Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries JH. No relevant relationship between glucose variability and oxidative stress in wellregulated type 2 diabetes patients. J Diabetes Sci Technol. 2011;5(1):86-92. https://doi.org/10.1177/193229681100500112
19. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7. https://doi.org/10.1001/jama.295.14.168
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. https://doi.org/10.1093/clinchem/18.6.499
21. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983;67(4):730-4. https://doi.org/10.1161/01.CIR.67.4.730
22. National Cholesterol Education Program. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (Adult Treatment Panel III). Circulation. 2002;106(25):3143-421.
23. Forthofer RN, Lee ES. Introduction to Biostatistics: A Guide to Design, Analysis, and Discovery. Elsevier; 2014.
24. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6(3):456. https://doi.org/10.4239/wjd.v6.i3.456
25. Chakraborty S, Verma A, Garg R, Singh J, Verma H. Cardiometabolic risk factors associated with type 2 diabetes mellitus: a mechanistic insight. Clin Med Insights Endocrinol Diabetes. 2023;16:11795514231220780. https://doi.org/10.1177/11795514231220780
26. Ma N, Zhang Y, Liu B, Jia X, Wang R, Lu Q. Associations of plasma 8-iso-prostaglandin F2α levels with fasting blood glucose and intraabdominal fat area in various glycometabolism populations. BMC Endocr Disord. 2021;21:6. https://doi.org/10.1186/s12902021008793
27. Liu JB, Li WJ, Fu FM, Zhang XL, Jiao L, Cao LJ, et al. Inverse correlation between serum adiponectin and 8-iso-prostaglandin F2α in newly diagnosed type 2 diabetes patients. Int J Clin Exp Med. 2015;8(4):6085.
28. Hulthe J, Hultén LM, Fagerberg B. Low adipocytederived adiponectin concentrations are associated with metabolic syndrome and small dense LDL particles. Metabolism. 2003;52(12):1612-4. https://doi.org/10.1016/S00260495(03)003135
29. Jelinek HF, Jamil DA, AlAubaidy HA. Impaired fasting glucose and 8-iso-prostaglandin F2α in diabetes disease progression. Br J Med Med Res. 2014;4(33):5229-37. http://dx.doi.org/10.9734/BJMMR/2014/11147
30. Gopaul N, Änggård E, Mallet A, Betteridge D, Wolff S, NouroozZadeh J. Plasma 8epiPGF2α levels are elevated in individuals with noninsulindependent diabetes mellitus. FEBS Lett. 1995;368(2):225-9. https://doi.org/10.1016/00145793(95)00649T
31. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, et al. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99(2):224-9. https://doi.org/10.1161/01.CIR.99.2.224
32. Zuo L, Prather ER, Stetskiv M, Garrison DE, Meade JR, Peace TI, et al. Inflammation and oxidative stress in human diseases: from molecular mechanisms to novel treatments. Int J Mol Sci. 2019;20(18):4472. https://doi.org/10.3390/ijms20184472
33. Rizwan S, Reddy Sekhar P, Malik Asrar B. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014. https://doi.org/10.1089/ars.2012.5149
34. Stanimirovic J, Radovanovic J, Banjac K, Obradovic M, Essack M, Zafirovic S, et al. Role of C-reactive protein in diabetic inflammation. Mediators Inflamm. 2022;2022:3706508. https://doi.org/10.1155/2022/ 3706508
35. Abulnaja KO, Kannan K, AlManzlawi AMK, Kumosani TA, Qari M, Moselhy SS. Sensitivity and specificity of biochemical markers for early prediction of endothelial dysfunction in atherosclerotic obese subjects. Afr Health Sci. 2022;22(2):286-94. https://doi.org/10.4314/ahs.v22i2.32
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Najlaa Qassim Muftin, Ghasaq Jabbar Kashtl (Autor)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
